In the last trading session, 1.12 million shares of the Cue Biopharma Inc (NASDAQ:CUE) were traded, and its beta was 1.70. Most recently the company’s share price was $1.08, and it changed around -$0.02 or -1.82% from the last close, which brings the market valuation of the company to $68.42M. CUE currently trades at a discount to its 52-week high of $3.25, offering almost -200.93% off that amount. The share price’s 52-week low was $0.45, which indicates that the current value has risen by an impressive 58.33% since then. We note from Cue Biopharma Inc’s average daily trading volume that its 10-day average is 0.8 million shares, with the 3-month average coming to 724.40K.

Cue Biopharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CUE as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Cue Biopharma Inc is expected to report earnings per share of -0.14 for the current quarter.

Cue Biopharma Inc (NASDAQ:CUE) trade information

Instantly CUE has showed a red trend with a performance of -1.82% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8400 on recent trading dayincreased the stock’s daily price by 41.3%. The company’s shares are currently down -59.09% year-to-date, but still down -36.47% over the last five days. On the other hand, Cue Biopharma Inc (NASDAQ:CUE) is -35.71% down in the 30-day period. We can see from the shorts that 1.78 million shares have been sold at a short interest cover period of 1.54 day(s).

The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 73.0% from its current value. Analyst projections state that CUE is forecast to be at a low of $2 and a high of $7.

Cue Biopharma Inc (CUE) estimates and forecasts

Cue Biopharma Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -42.71 percent over the past six months and at a 36.94% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 50.00% in revenue this quarter, and will report an increase of 40.00% in the next quarter. The year-over-year growth rate is expected to be 71.40%, up from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 1.7M in revenue for the current quarter. 3 analysts expect Cue Biopharma Inc to make 1.27M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.82M and 1.72M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -6.58%. Forecasts for the next quarter put sales growth at -26.17%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.55%.

CUE Dividends

Cue Biopharma Inc’s next quarterly earnings report is expected to be released in December.

Cue Biopharma Inc (NASDAQ:CUE)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.55% of Cue Biopharma Inc shares, and 23.59% of them are in the hands of institutional investors. The stock currently has a share float of 23.72%. Cue Biopharma Inc stock is held by 69.0 institutions, with BLEICHROEDER LP being the largest institutional investor. By 2024-06-30, it held 5.7849% of the shares, which is about 2.86 million shares worth $3.55 million.

SLATE PATH CAPITAL LP, with 4.8567% or 2.4 million shares worth $2.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.